Mochi Health vs Fridays: Onboarding, Titration, Follow-Up

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

You are reading a PlexusDx Education Hub comparison covering GLP-1 medicine, weight-management protocols, and the genetic factors underneath them. Open the Peptides & GLP-1 hub.

This is independent editorial coverage. PlexusDx has no commercial relationship with Mochi Health or Fridays and includes no affiliate links or paid placement.

Full head-to-head: PlexusDx vs Fridays →

Comparing Mochi Health and Fridays is less about which drug they dispense — both work in the GLP-1 space — and more about the experience of using each: how you onboard, how doses are adjusted, and how follow-up is handled. This review walks through that experience for both, then turns to a metabolic factor neither is built to measure. As of April 2026.

Two paths into the same drug class

Both Mochi Health and Fridays are telehealth routes to GLP-1 therapy, so the medications overlap. What differs is the shape of the program around them — the provider relationship, the pharmacy pathway, and the day-to-day support — which is where a real comparison lives. Two people could take the identical medication through these two services and still describe very different experiences, because the surrounding program is doing much of the work.

Mochi Health in brief

Mochi Health (Mochi Health) operates as telehealth with insurance support. A program of this type pairs a virtual evaluation with a provider-issued prescription routed to a retail pharmacy for FDA-approved product or a 503A compounding pharmacy for compounded semaglutide or tirzepatide. Confirm current structure on Mochi Health's official website.

Fridays in brief

Fridays runs as telehealth paired with a compounding-pharmacy pathway. Its onboarding flow, medication tiers, and follow-up model are described on Fridays' official website, and those details can change, so check them directly when you evaluate the program.

Onboarding, titration, and follow-up

Across these programs the arc is similar: an intake covering weight, history, and medications; a clinician's eligibility review; a prescription routed to the appropriate pharmacy; then follow-up to adjust dose and manage side effects. The differences that matter are provider type, how responsive support is, and how titration decisions are handled — details worth comparing side by side.

What the trials actually measured

The clinical evidence attaches to the compounds, not the platforms. STEP evaluated semaglutide for weight management (NEJM, 2021), SURMOUNT did the same for tirzepatide (NEJM, 2022), and SURMOUNT-OSA studied tirzepatide in obstructive sleep apnea (NEJM, 2024). Effect sizes depend on compound, dose, and population, and individual results vary. None of that evidence, importantly, is generated by a telehealth brand; it predates and stands apart from any platform now offering the medication.

The genetic context missing from both

What neither program's onboarding captures is your inherited metabolic biology. GLP1R encodes the receptor these compounds bind, MC4R sits at the center of satiety and energy balance, and an FTO variant shapes appetite regulation. The PlexusDx Precision Peptide Genetic Test surveys 14 pathways, 49 peptides, 150+ genetic insights across that map, describing your baseline biology rather than forecasting how a given medication will work for you.

How PlexusDx layers genetics onto the protocol

PlexusDx provides semaglutide and tirzepatide through its Weight Management Protocols, including a flat $129/month microdose option. Bringing in the Precision Peptide Genetic Test first means your onboarding starts from pathway data — a test-before-you-invest approach that program intake forms alone don't provide.

No affiliation: PlexusDx is independent of Mochi Health and Fridays and has no commercial relationship with either.

Keep reading on PlexusDx: GLP 1 Hormone, GLP 1 Receptor Agonist, GLP 1 What Is, and What Is GLP 1.

Editorial note: this comparison is educational and independent. PlexusDx has no relationship with Mochi Health or Fridays and offers semaglutide and tirzepatide through its own protocols. The Precision Peptide Genetic Test analyzes gene-influenced peptide pathways and does not predict medication response. Consult a qualified provider before starting any peptide protocol.

Frequently Asked Questions

How do onboarding experiences differ between Mochi Health and Fridays?

Both start with an intake and clinician review, but they differ in provider type, how quickly you are evaluated, and how follow-up is delivered. Fridays centers on a compounding pathway while Mochi adds insurance support. Compare each program's described onboarding and support flow on its own website.

Who manages dose titration in these programs?

In telehealth GLP-1 programs, a licensed clinician typically guides titration through follow-up visits or messaging, adjusting the dose and addressing side effects over time. The responsiveness and format of that support vary between Mochi Health and Fridays, so it is worth confirming how each handles ongoing care.

Does the medication differ between the two?

Both work with the same GLP-1 drug class — semaglutide and tirzepatide — though the dispensing pathway differs, with Fridays emphasizing compounded products. The pharmacology comes from the compound itself, so the platform you pick changes the experience and access model, not how the molecule acts.

Where does genetic testing fit into the experience?

The Precision Peptide Genetic Test does not predict response or rank programs. It maps pathway variants like MC4R, and FTO that describe your metabolic baseline, giving you information to bring into onboarding and follow-up conversations with a provider at either program.

This article is part of the PlexusDx Education Hub. Explore more Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.